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Teaser phrase 
 
How the clinical practice and expertise may associate with the computational drug 
development methods in a more effective definition of new molecules with potential 
therapeutic effect. 
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Research highlights 
 
Drug development by pharmaceutical companies generally depends of commercial 
interests and market opportunities, limiting the investment in innovation. 
 
Academic research lacks funding and acts on specific fields, without receiving input 
from clinicians or the industry. 
 
Clinical needs and therapeutic problems are not always a priority in drug development. 
 
Clinical expertise is not taken into account in project creation and definition of the 
future therapeutic viability of newly designed drugs. 
 
Translational research by combining clinical practice, applied research and 
computational chemistry can surpass limitations at present.  
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Abstract 
 
Traditionally, the first step in the development of new drugs is the definition of the 
target, by choice of a biological structure involved in a disease or by the recognition of a 
molecule with some degree of a biological activity that presents itself as druggable and 
endowed with therapeutic potential. The complexity of the pathophysiological 
mechanisms of disease and of the structures of the molecules involved creates several 
challenges in this drug discovery process. These difficulties also come from 
independent operation of the different parts involved in drug development, with little 
interaction between clinical practitioners, academic institutions and large 
pharmaceutical companies. Generally, research in this area is purpose specific, 
performed by specialized researchers in each field, without major inputs from clinical 
practitioners on the relevance of such strategy for future therapies. Translational 
research is a path of shifting the way these relationships operate towards a process in 
which new therapies can be generated by linking experimental discoveries directly to 
unmet clinical needs. Computational chemistry methods provide valuable insights on 
experimental findings and pharmacological and pathophysiological mechanisms, allow 
the virtual construction of new possibilities for the synthesis of new molecular entities, 
and pave the way for informed cost-effective decisions on expensive research projects. 
This review focus on the current computational methods used in drug design, how they 
can be used in a translational research model that starts from clinical practice and 
research-based theorization by medical practitioners and moves to applied research in a 
computational chemistry setting, aiming the development of new drugs for clinical use. 
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Introduction 
 
The majority of drugs available today come from different approaches, having in 
common the following development steps: target identification and validation, lead 
identification, lead optimization and non-clinical trials. The complete process generates 
active molecules that are evaluated in clinical trials before being subjected to approval 
as new drugs for disease treatment [1]. Traditionally, the method consists in 
constructing hypotheses on a molecular component of a particular mechanism in a 
specific pathology, theorizing on how to overcome a disease-based pathophysiological 
mechanisms and finding small molecules to deliver the corrective solution. The method 
also uses another common aspect of these approaches that has been the traditional 
concept of a “receptor” as a target [2].  
Strategies in discovering small molecules that can fulfill the hypothesis have 
varied over the years, with isolation of lead compound from plants and animals, use of 
empirical chemistry and applied pharmacology, development of rational drug design 
based on new knowledge in physiology and pathophysiology and drug repositioning [2]. 
The isolation of lead compounds from plants and animals delivered some of the most 
potent and widely used drugs today. Mankind has been using natural products for 
therapeutic purposes for a very long time. The extracts from plants and animals usually 
contain a mixture of ingredients, either beneficial or adverse. Early drug development 
focused on identifying the entities responsible for the beneficial effects and purifying 
them. The use of a single molecule facilitates the evaluation of safety and efficacy, 
contrary to the use of a complex mixture. Drug development based on extracts from 
animals and plants is performed mainly by two methods: the research of ethnic remedies 
looking for evidence of a therapeutic effect and the screening of different extracts of 
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plant and animal parts against batteries of biological and genomic test systems looking 
for a potentially interesting biological action. This strategy creates several difficulties as 
adequate drug quantities obtained by chemical extraction are often a limiting factor. 
Also, the search of new molecules is frequently developed without a strategy involving 
prior clinical needs, the definition of underlying pathophysiological mechanisms to 
which a disease can be treated or the delineation of an eventual future place in therapy. 
Additionally, the entities obtained from plants or animals are often large and complex, 
making them difficult to synthesize [3]. The use of empirical chemistry coupled with 
applied pharmacology is one of the most productive sources in drug development. The 
identification of a pharmacophore consists in the design of a simple molecule with 
similar pharmacological activity. The synthesized entity can then serve as a model for 
further modifications to improve pharmacokinetics and pharmacodynamics. This 
process is lengthy, strenuous and expensive, involving synthesis of a range of related 
compounds, molecule purification, and structure characterization, pharmacological and 
toxicological properties testing [2]. The advent of combinatorial chemistry and high-
throughput screening (HTS) allowed that a huge number of related molecules could be 
produced in lesser time. This approach depends on automation to synthesize and screen 
a high number of molecules to find all those that can enable a desired biological action. 
This strategy has the advantage of requiring minimal compound design or minimal prior 
pathophysiological and pharmacological knowledge. Although the technologies 
required in screening large libraries of compounds have become more efficient, the 
development of suitable systems in which compounds are tested is still challenging and 
the methods are expensive. Furthermore, although traditional HTS often results in 
multiple hit compounds, some of which are capable of being modified into a lead and 
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later a novel therapeutic, the hit rate for HTS is often extremely low [4]. Again, the 
development is mostly made without taking into account the clinical needs [5].  
The use of rational drug design based on new knowledge in physiology and 
pathophysiology is one of the main areas in which the clinical practitioner can take a 
role in drug development. Our understanding of physiology and pathophysiology has 
improved substantially and there has been an increase in accuracy of technologies 
available for drug design. Clinical practitioners should be able to develop and evaluate a 
novel research proposal aiming the characterization of disease mechanisms and 
determine its potential applicability and value as a therapeutic intervention towards 
different putative targets. These putative targets should then be evaluated in silico on 
their properties. The use of computational chemistry allows the prediction of the 
structure of the binding site of a receptor in three dimensions from its amino-acid 
sequence. Based on this information, it is possible to virtually design groups of 
molecules that may bind with high affinity to that site [6].  
The drug repositioning strategy is the second of the main areas in which the 
clinical practitioner can be an active part in drug development.  Several effective and 
lucrative drugs were repurposed, without their development being determined for their 
present indications. Serendipitous discovery of new pharmacological effects and their 
therapeutic applicability by different old drugs of the same therapeutic group have led to 
the implementation of new uses [7].  The identification of previously unknown 
pharmacological effects of a known drug and the identification of the nature of adverse 
effects of drugs in clinical practice can serve as basis for drug discovery. There is strong 
evidence that such off-target interactions, or polypharmacology, are common among 
many approved drugs [8]. The use of computational chemistry can be explanatory on 
how a single molecule can act on multiple targets, by definition of its form, size, 
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analogy with endogenous ligands or other drugs, charge distribution and 
complementarity with receptors. The chosen molecule can constitute a lead compound 
for further research. The fact that the first contact with these adverse effects comes from 
the physician may determine its choice where to pursue and where not to pursue, in 
view of its relevance for future therapy. 
Although all of these strategies are currently in use by research teams in 
academic groups, biotechnology companies and pharmaceutical industries, they operate 
independently, each with its own objectives and methods. Furthermore, the problem of 
not supplying the needs present in the everyday clinical practice is as relevant as ever. It 
must be accepted by all entities involved that the traditional ways of developing drugs 
are becoming ineffective and cannot accompany the rapid developments in health 
sciences [9]. Studies in the field of drug discovery and development show that large 
pharmaceutical companies do not present themselves as leading examples in innovation, 
but have commercial interest as their major concern [10]. This also has repercussion in 
the development of new drugs based on the fraction of the market that a determined 
therapeutic group may achieve and not on the clinical needs. The public sector 
represented by academics and the biotech companies are becoming the main 
contributors in drug discovery [11]. The problem with these sectors is that academic 
researchers or small biotech companies are often not well-trained in clinical research. 
There is also the issue of lack of training in business strategies resulting in little access 
to the necessary funding for generating research data attractive to investment. 
The final point is that the lack of communication between all the referred parties 
has resulted in many valid ideas not being developed in research and many drug 
researches being unproductive. A new model for the development of new drugs is 
emerging called translational research and represents a more focused strategy for 
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creating new drugs than the traditional model [12].  The basic concept consists in 
combining the needs of patients with research-originated concepts provided by clinical 
practitioners and with state-of-the-art data on the subject as the basis for planning new 
therapies. 
In this review we will discuss how translational research may be applied in 
combining patient and clinical unmet needs with computational drug discovery based on 
clinical expertise. 
 
Translational research and the use of computational strategies 
 
The definition of translational research is not consensual, with multiple 
definitions for its meaning and its use [13]. The expression translational research 
provided here is based on the notion that the development of new drugs must relate 
directly to patient needs and that could be performed by coupling computational and 
laboratory research with observations originated in clinical practice. The achievement of 
the translational approach in drug design is the incorporation of a specific clinical need 
from the beginning of the research process. The traditional research-based drug design 
is based on applying data from basic cellular mechanisms to the development of new 
therapies. Translational research encompasses this concept, with the advantage of 
targeting mechanisms underlying clinically relevant problems and developing 
molecules with potential action over those issues directly. Translational research covers 
the main components that should be involved in drug development: clinical practice and 
expertise, laboratory investigation, and health benefits in society [14]. The process 
involves two main stages, being one of them the connection between clinicians and 
applied research, and named T1.The other stage is named T2 and corresponds to the 
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connection between clinicians and community [13]. The T1 concept is mainly 
performed in universities or other institutes of higher education, and focus on the 
laboratory discoveries that relate to specific clinical endpoints. The proximity between 
clinical departments of a central hospital and the academic researchers of the associated 
faculty or university enables laboratory scientists and practicing physicians to gather 
and provide the discussion on how clinical practices and laboratory data can be applied 
in drug design for different diseases. The unmet needs among patients and the 
quantitative and qualitative different response to existent drugs, recorded by physicians, 
can be shared with laboratory researchers. This communication allows the planning of 
potential solutions and the creation of new projects based on the prior knowledge of the 
underlying molecular mechanisms of diseases and drugs. The T2 concept integrates 
community outreach programs with clinical practices, with the aim of providing a 
means for understanding how well treatment strategies are working at a population 
level. This notion may also allow the identification of needs of patients and the 
quantitative and qualitative different response to existent drugs for posterior debate and 
consequent research [14]. 
The effective communication and regular collaboration between all the involved 
parts are the basis of translational research and can facilitate the interaction between 
clinicians that treat patients and computational chemistry scientists that could explore 
the data provided by the first. The clinicians would provide patient and clinical issues in 
need of solution, input in diseases lacking therapeutic options, applicable 
pathophysiological mechanisms for drug design directed to treatment of yet unsolved 
problems, interesting drug actions and adverse effects or patient responses to treatments. 
The information thus provided would serve as a starting point in the definition of 
biological targets and lead compounds, being then applied to the virtual design of 
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molecules for further selection based on activity prediction, by use of different 
computational tools. The predicted potentially active molecules could then be 
synthesized and biologically tested (Figure 1). 
Computational methods are capable of increasing the rate of discovery of hit 
compounds because it uses a much more targeted approach. It has the advantages of 
attempting to explain the molecular basis of a therapeutic activity and the prediction of 
possible derivatives that could improve activity [4]. There are many computational 
strategies applicable to drug design. One way to classify these methods is by 
categorizing them as either “Ligand-based methods”, where discovery of opportunities 
initiates from knowledge about small molecules and their action, or “Structure-based 
methods”, where discovery initiates from knowledge about macromolecules involved in 
a disease pathophysiology or symptomatology. The approaches in drug design using 
ligand-based methods can be systematized in 4 main categories: activity and chemical 
similarity, adverse effects similarity, indication reallocation and shared molecular 
pathology. As for the approaches in structure-based methods, its main basis consists in 
pathophysiological mechanism definition, although the concept of shared molecular 
pathology can also be applied. The referred systematization can be described as 
followed: 
• Activity and chemical similarity: The structure and chemical properties 
of a molecule correlate with its pharmacological action. The study of shared 
physicochemical characteristics between molecules presenting the same 
biological activity allows the definition of criteria for new molecule design. This 
concept is named quantitative structure-activity relationships (QSAR) and 
constitutes a rational basis for drug development [15]. This concept is still quite 
valid and useful in designing molecules based on an endogenous ligand of 
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known structure, to develop agonists or antagonists of its activity. The same 
approach can be applied to previously approved drugs, designing new ones to 
overcome pharmacokinetic problems or improve efficacy and safety. It can also 
be quite helpful when combined with the concept of adverse effects similarity, in 
the explanation and improvement of an interesting action, for the design of new 
drugs. 
• Adverse effect similarity: Existent drugs can be correlated to clinical 
effects through their adverse effects, which represent unintended biological 
actions of the active molecule. The unintended actions can be beneficial in a 
determined disease condition, posing a possibility of a treatment that can be 
further researched. Adverse effects also provide a means to connect drugs 
between themselves to establish QSAR or a pharmacophore, even in cases where 
the precise pharmacological mechanism of the adverse effect is unknown. 
Adverse effects also provide a means to connect drugs to diseases. The 
manifestation of an adverse effect can be similar to that of a disease, raising the 
possibility that the underlying physiological process may be similarly disturbed 
by both the drug and the disease pathophysiological mechanism [16]. 
• Indication reallocation: The knowledge of drug indications for disease is 
a tool for definition of new lead compounds. Diseases can be considered similar 
if they share a significant number of drugs in the established therapeutic 
regimens. In each pair of similar diseases, the drugs that are currently used 
against only one of the diseases can then be considered as candidates as drugs 
for the other disease in the pair [17]. One of these drugs can be defined as a lead 
compound. The lead compounds found can serve as a basic structure for the 
design of new structures that share chemical similarities. 
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• Shared molecular pathology: the existence of some common aspect of 
underlying molecular pathophysiology between two diseases allows that a drug 
which presents a known pharmacological mechanism can be repositioned from 
one indication to another. This strategy allows drug repurposing and also the 
definition of new lead compounds [18]. 
• Pathophysiological mechanisms: the definition of the macromolecules 
involved in a disease and the way each one is affected is one the basis of the 
rational drug design. The definition of the tridimensional structure of the 
selected macromolecules, by x-ray crystallography or other experimental 
method, allows their use in the design of virtual molecules and to predict their 
ability to associate with the active site that may result in a biological action with 
potential usefulness in therapy [19]. 
Ligand-based approaches might be preferred, if there is interest to understand 
more precise pharmacological properties, or if rich pharmacological and chemical data 
for drugs or endogenous small molecules is available. Structure-based approaches may 
be preferred when the purpose is to focus on a specific disease. While each of these 
approaches present unique informatic challenges, successful strategies often incorporate 
elements from both methods [20]. There are several programs created for the purposes 
and techniques referred for ligand-based and structure-based methods of drug design. 
The number of computational tools applicable in drug discovery campaigns suggests 
that there are no fundamentally superior techniques, but the performance of methods 
varies greatly with target protein, available data, and available resources [4]. Although 
effective in their function, there are situations where there is the need of a prior or 
further study of the receptors selected, of the lead compounds and of the new molecules 
designed by one or both methods. It is common to use software for molecular 
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mechanics and dynamics simulations, quantum mechanics calculations, absorption-
distribution-metabolism-excretion/toxicity (ADME/T) predictions, molecular 
visualization and chemoinformatics, each with its own applicable features in drug 
design (Box 1).  
 
Ligand-based methods for drug design 
 
Ligand-based methods are based on the principle which states that similar 
chemical structures tend to present similar biological activities [21]. These methods rely 
on prior knowledge of biological ligands or prior drugs and macromolecular structures, 
generally not being applicable in cases where no ligands for a given putative receptor 
exist. The main methods are 3D pharmacophore modeling and QSAR. 
3D pharmacophore modeling can be used in the absence of a receptor structure. 
The prerequisite is the condition of having a set of known ligands representative of 
essential ligand–macromolecule interactions from which can be extracted the common 
chemical features from their 3D structures. IUPAC defines pharmacophore as “an 
ensemble of steric and electronic features that is necessary to ensure the optimal 
supramolecular interactions with a specific biological target and to trigger (or block) its 
biological response” [22]. The common chemical characteristics that are usually 
selected are the presence of hydrogen-bond acceptors, hydrogen-bond donors, 
hydrophobic regions and positively or negatively charged groups. A 3D pharmacophore 
can also be derived from a receptor structure by observing the interactions between 
macromolecule and ligand. As such, shape and excluded volume information can be 
added to the pharmacophore. This has the advantage of designing molecules that not 
only have the selected binding features but can also predictively fit into the active site. 
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By definition, a pharmacophore is based on the concept of similarity between ligands, 
with the definition of an essential backbone for activity and all the substituents that can 
determine the physicochemical properties that lead to biological activity. The concept of 
pharmacophore has found widespread use in hit-and-lead identification and also in 
following lead optimization, being very successful in drug discovery [23]. 3D 
pharmacophore generation from a set of ligands involves two main steps. The first one 
corresponds to the definition of the conformations of each ligand most probably 
involved in the interaction with the receptor. The second one is the alignment of the 
multiple ligands (in their selected conformations) to determine the common chemical 
features needed to design a 3D pharmacophore. There are two types of pharmacophore 
models. One is the 3D model based on QSAR that is established with a relationship 
with the degrees of activity. The most common model involves a training set with only 
active ligands. The new compounds can be estimated qualitatively by whether they 
match the established 3D model [24]. The application of the 3D pharmacophore 
technique is demonstrated by the work in which were developed CB1 cannabinoid 
receptor antagonists for obesity treatment.  Unified pharmacophore models for the CB1 
receptor ligands were developed by incorporation into the superimposition model for 
the known cannabinoid agonists. From this information it was possible to design 
antagonists by introducing aromatic rings for steric hindrance [25]. The success of this 
approach came from the application of the concept of activity and molecular similarity, 
using a 3D pharmacophore definition method. 
QSAR modeling is also an established method, being used as a computational 
tool for rationalizing and correlating physicochemical properties with experimental 
binding data or inhibitory activity of chemical compounds [26]. QSAR consists mainly 
in two different techniques, 2D and 3D QSAR. 2D QSAR consists in defining an 
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equation that can be used to predict activity based on descripted physicochemical 
properties of a compound. The equation is a correlation between a set of independent 
variables (chemical descriptors) and a dependent variable such as receptor binding 
ability for the compound of interest. The equation is established and applied using 
algorithms like regression-analysis algorithms, multivariate analysis algorithms, 
heuristic algorithms or genetic algorithms [27]. 3D QSAR is a QSAR approach based 
on a set of predefined 3D molecular structures. The molecular descriptors used contain 
physicochemical properties and conformational coordinate-derived information. This 
technique uses a 3D grid of points around the molecule, each point having properties 
associated with it that can vary in a field-like manner from point to point, such as steric 
interactions or electrostatic potential. Therefore, this method can be used for predicting 
the binding capability of a ligand to the active site of a specific receptor. The 
construction of the 3D-QSAR model needs a training set, containing at least 20 active 
compounds with activity over the selected pathophysiological mechanism. The next step 
is to generate conformations and alignments of the training set molecules. A 
dimensionality reduction step is then inserted to extract the features of the 3D 
interaction field that are most strongly determining the activity before the actual 
predictive model is built. At last, a test set with some known active molecules is used to 
examine the prediction ability of the built 3D QSAR model [28]. The applicability of 
the QSAR method is exemplified in a research work that involved the computational 
design approach to screen biomaterials with anti-atherogenic efficacy. Several 
amphiphilic macromolecules were quantified in terms of 2D and 3D descriptors. QSAR 
models with the referred descriptors for anti-atherogenic activity were constructed by 
screening a total of 1164 parameters against the corresponding, experimentally 
measured potency of inhibition of oxidized LDL uptake in human monocyte-derived 
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macrophages. Five key descriptors were identified to provide a strong linear correlation 
between the predicted and observed anti-atherogenic activity values, and were then used 
to correctly forecast the efficacy of three newly designed biomaterials. Thus, a new 
ligand-based drug design framework was successfully adapted to computationally 
screen and design biomaterials with cardiovascular therapeutic properties [29]. The 
research presented is a good example of translational research, involving a clinical need 
in atherogenesis prevention, computational chemistry and biomaterials research.  
Ligand-based methods can be used to determine minimal and common structures 
predictively responsible for biological activity. The data needed to start a research 
program is the identification of endogenous ligands or exogenous compounds that 
present the same activity (activity and chemical similarity, adverse effects similarity, 
indication reallocation). This information can be provided by clinicians of a designed 
specialty, bearing in mind the therapeutic relevance of the data. The 3D structure of the 
selected molecules can be used to establish a 3D pharmacophore or QSAR models for 
further design of new compounds with potential pharmacological action. Several other 
examples could be presented, with different strategies of approach, from activity and 
molecular similarity, adverse effects similarity, indication reallocation and shared 
molecular pathology, as seen before. One of these examples is the adverse effects 
similarity presented by cyclobenzaprine, which reportedly originated serotoninergic 
syndrome. A virtual screening provided evidence that cyclobenzaprine blocks, with 
moderate to high potency, the serotonin and norepinephrine transporters as well as five 
serotonin receptor subtypes at therapeutically relevant concentrations [30].  
 
Structure-based methods for drug design 
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Structure-based methods are strategies that explore macromolecular structural 
information, combined with scoring functions, in order to predict ligand–receptor 
affinity. Ligands are defined as interaction partners for a given receptor. This concept 
has been recently reverted to dock one small molecule against a panel of multiple 
receptors [31]. 
Molecular docking is the preferred method to investigate how a ligand interacts 
with the receptor, when the structure of the target macromolecule is known. Molecular 
docking consists in an algorithm that determines how a molecule may establish 
connections in the binding site of a putative receptor and tries to predict the strength of 
the interaction. This method is an attempt of mimicry of the process of formation of a 
non-covalent complex by bringing together a macromolecular receptor and a ligand. 
The virtual complex obtained reveals the electrostatic and steric complementarity 
between the macromolecule and its different ligands. A docking algorithm performs an 
attempt of prediction of the correct positions of ligands at the binding site of a 
macromolecule and establishes a ranking of the obtained poses. The accomplishment of 
position prevision and accurate ranking is challenging, and so far none of the known 
docking programs were able to solve both of them perfectly. Prediction of possible 
binding positions in an active site is more straightforward, being performed by most 
programs. Because of its success at binding position prediction, docking is a well-
established drug-design technology employed in structure-based methods [32].  The 
prerequisite for docking techniques and structure-based drug design is the existence of a 
3D structure of a target, preferably in complex with a ligand. The 3D structure may be a 
crystallographic x-ray structure or an NMR structure. The structure of the ligand or of 
known active drugs can lead to the design of new molecules, based on the previously 
described ligand-based methods. The observation of the form, size, charge and 
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electrostatic potential distribution of the active site can also lead to the design of new 
virtual compounds. Once an appropriate set of molecular candidates has been designed, 
they can be docked into the active site allowing a further reduction of the number of hits 
based on the scoring functions. The docking results are examined visually or submitted 
to further computational calculations to choose candidates for synthesis and biological 
assays [33]. An example of the referred sequence of research work is the design of a 
series of coumarins to act as TNF-α converting enzyme inhibitors. The compounds were 
designed to bind in a pocket of the enzyme based on the docking study. Twelve 
analogues were synthesized and most of compounds were active in vitro, showing TNF-
α converting enzyme inhibition as well as cellular TNF-α inhibition [34]. The prior 
definition of a pathophysiological mechanism allowed the definition of a target for drug 
development. The clinical importance of this intervention is demonstrated by the fact 
that overproduction of TNF-α is responsible for many autoimmune disorders such as 
rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis, among others. The 
clinical success of anti-TNF-α biologic agents for treating inflammatory diseases, such 
as infliximab or adalimumab, have confirmed that inhibition of TNF-α is  an important 
approach for an effective treatment for several autoimmune diseases [35, 36]. Their use 
permitted overcoming a clinical need and an important health problem in populations, 
as is intended in translational research. 
Homology modeling is a useful approach to develop structure-based drug design 
when the 3D model of a target protein is needed and whose structural configuration is 
not experimentally determined. The requisites here are the availability of the sequence 
of its amino acids and the experimental determined 3D structure for one or more 
sufficiently proteins similar to the selected target. Homology modeling performs the 
assembling of a model of the target protein from its amino acid sequence using the 
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experimental 3D structures of related homologous proteins as templates [37]. The 
concept is based on the experience that similar amino-acid sequences lead to similar 3D 
topographies. The conservation of regions between the active site of the studied protein 
and the template structures gives good accordance [38]. The quality of a homology 
model is consequent to the quality of the chosen template structure and the sequence 
alignment performed, and is biased by low sequence identity between the target and the 
template. Models with more than 50% sequence identity are believed to be accurate 
enough for drug design application. In this range, the root-mean-square deviation 
between the experimental structure and the model may be around 1 Å, which is 
equivalent to the typical resolution of structures solved by NMR. In the 25–50% 
identity range, errors can be more severe and are frequently located in the flexible loops. 
The homology model can be used for the assessment of druggability and mutagenesis 
experiments, but should be applied with caution for drug design. Below 20–25% 
sequence identity, a model is usually not usable for drug design because serious errors 
can occur [37]. Homology modeling was used in the prediction of the 3D structure of 
the protein Rv3802c. Rv3802c is an essential cell wall lipase of Mycobacterium 
tuberculosis. The modeling of its structure for the first time provided insight in 
identifying the ligand binding sites and potential inhibitors effective towards 
mycobacterial proteins. Two diverse molecules have been identified as potential 
inhibitors effective towards Rv3802c by docking on the modelled macromolecule [39].  
Structure-based methods can be used to study putative receptors involved in a 
pathophysiological process associated with a disease that constitutes a relevant problem 
in society (shared molecular pathology, pathophysiological mechanism definition). The 
importance of the disease can be determined by the team of physicians involved. The 
choice of the target in the pathophysiological process can also be determined by the 
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clinicians, supported by experimental evidence and clinical expertise. The selected 
macromolecules can be studied using structure-based methods to determine their 
conformation and configuration. The interaction with the proper endogenous ligand and 
with new potential drugs can also be simulated.  This work allows the prediction of 
activity and the selection of the candidates for synthesis and activity evaluation. The 
discovery that raltegravir acts as a metnase inhibitor is an example on how structure-
based methods can be used in drug repurposing and development. Metnase is a DNA 
repair enzyme which can constitute a potential target for adjuvant cancer therapy. 
Raltegravir was identified as a metnase inhibitor via structure-based virtual screening 
studies, being in fact confirmed that it presents the predicted action, at doses that are 
roughly ten times higher than the currently approved maximum dose [40]. 
 
Databases containing bioactivity records  
 
The development in recent years of databases integrating diverse types of data 
such as structural data and drug adverse effects brought a powerful tool to drug design. 
The information that these databases carry was previously hardly accessible in 
electronic form at the public domain [41].  The databases differ in functionality, but 
have a common purpose of integrating different types of data. These databases may be 
just molecular structure collections, or provide relevant type of data, such as 
quantitative bioactivity of the molecules and their macromolecular targets, as well as 
data on targeted illnesses. Some of the available databases attempt to link small-
molecule data, biological targets data and available assay data [42, 43]. There are 
millions of bioactivity data points available, which can be used for ligand-based or 
structure-based methods. The presentation of a clinical need in therapeutics can lead to a 
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search in these databases of compounds that show activity in a given problem. The 
selected compounds can be further studied by ligand-based methods to determine the 
minimal and common structure predictively responsible for activity, constituting the 
base for new drug design (activity and chemical similarity, adverse effects similarity, 
indication reallocation). In the same manner, the databases can provide information on 
putative receptors involved in a pathophysiological process and the definition of a 
common mechanistic ground with the subject presented by a team of physicians. The 
putative receptors can be studied using structure-based methods to determine their 
conformation and configuration, the process in which the interaction with the selected 
small molecules proceeds, and the simulation of interaction with new virtual molecules 
that could be developed to potentially active compounds (shared molecular pathology, 
pathophysiological mechanism definition). The presentation of a newly found adverse 
effect of a drug can start a selection of molecules that present the same action. The 
application of ligand-based methods allows the definition of the chemical properties of 
the different molecules presenting the same activity. New molecules can be designed 
presenting the molecular features determined as essential for activity (adverse effects 
similarity). The ZINC chemical library [44] is an example of a library used in a ligand-
based similarity search, for the identification of potential anticancer compounds. The 
search was directed to the urokinase receptor. This receptor serves as a docking site to 
the serine protease urokinase-type plasminogen activator to promote extracellular 
matrix degradation and tumor invasion and metastasis. The search for inhibitors gave 
127 derivatives that share the core structure of the molecules that act on the urokinase 
receptor. These derivatives were purchased and tested for inhibition of urokinase 
receptor binding to serine protease urokinase-type plasminogen activator. Cellular 
studies showed that compounds blocked invasion, migration and adhesion [45]. 
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Future prospects 
 
The combination of clinical practice and expertise with computational chemistry 
can be accomplished in the form of a translational discovery center. This center consists 
in an entity with a structure of research based on the creation of teams of clinicians of a 
given specialty, computational chemistry scientists and medicinal chemists, with the 
purpose of defining projects for drug development oriented to meet patient and clinical 
needs. The joining of knowledge can allow a more rational drug design, with a great 
input from clinicians in target definition and validation or lead compound selection. 
That creates the basis of research work from which new drug designs are pursued. The 
design obtained can be further developed in partnerships with different contributors. 
The concept may lead to a new style in the field of drug design. It has the potential to 
benefit all parties, pursuing the purpose of new and better drugs based on community 
needs and not simply on commercial interests. It can also provide academic researchers 
with access to funding and expertise from biotech and pharmaceutical companies, while 
providing opportunities for the pharmaceutical companies to access innovative research. 
This model for integrative drug development allows the potential funding and further 
development of research by connecting academia, industry, venture capital firms, 
philanthropic organizations, advocacy groups, independent consultants and contract 
research organizations. The concept is of a technology incubator for the design and 
possible creation of new effective drugs based on society concerns and clinical needs. 
The success of this concept in drug discovery will depend on the effectiveness of 
communication of the parts involved and the willingness to prioritize research directed 
to aspects of disease and therapy that benefit the patient.  
 23 
Translational research is a central new strategy in the field of drug development. 
The combination of clinical expertise and computational chemistry could be an effective 
way of applying the concept.  
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Figure 1 
 
Proposed translational model of drug development. The global process of drug 
development, with the stages in which is applied the translational approach between 
clinical practice and computational chemistry. 
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Box 1 
 
Auxiliary computational techniques for drug design 
 
Molecular mechanics and dynamics software 
 
Molecular dynamics simulations are based on Newton’s equations of motion. Molecular 
dynamics is very useful for understanding the dynamic behavior of proteins or other 
biological macromolecules, from fast internal motions to slow conformational changes 
or even protein-folding processes. These simulations incorporate flexibility of both the 
receptor and the ligand, coming closer to the ideal of induced fit by enhanced 
complementarity and interaction Molecular dynamics simulations integrate explicit 
solvent molecules, creating a more mimetic environment of the biological conditions, 
adding the solvent’s effect on the stability of the ligand–protein complexes [46]. Thus, 
the results from MD simulations can be employed as target for docking studies or the 
technique can be employed to refine docked complexes [33].  
 
Quantum mechanics software 
 
Being the nuclei held together by electron orbitals governed by the laws of quantum 
mechanics, ligand-based and structure-based methods can be addressed using quantum 
mechanics methods. This fact as become reality due to the increase of central processing 
unit performance and the improvement of algorithms and software [47]. Quantum 
mechanics methods can be used to model small to medium-sized molecules, radicals 
and estimate activation energies for chemical and enzymatic reactions. The applications 
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in drug design include calculation of energies and optimization of structures of ligands 
and protein–ligand complexes, calculation of atomic point charges applicable to 
correcting the binding mode of a ligand obtained from docking studies, calculation of 
free binding energies and build of QSAR models [48]. 
 
ADME/T software 
 
ADME/T prediction software is capable of predicting potential risks in 
pharmacokinetics and toxicology, with great benefit in the design of molecules that not 
only potentially interact with the putative receptor selected but also accomplish the 
criteria for being used as a drug in a safe dosage and posology. The concept consists in 
the development of statistical models supported by QSAR. The relationships established 
are not determined for prediction of activity over a receptor involved in a disease but to 
predict ADME/T features [49].  
 
Molecular visualization software 
 
Molecular visualization programs are graphical user interfaces, through which the users 
can visualize and analyze their models and results, and can generate graphics for 
publications or reports.  There is the possibility of analysis of density maps, 
supramolecular assemblies, sequence alignments, docking results, trajectories and 
conformational ensembles [50].  
 
Chemoinformatics software 
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Chemoinformatics software consists in computational tools that assist in the 
acquirement, analysis and management of data of chemical compounds and their 
properties. The programs used prioritize on the management of information. Such 
requirements were frequently regarded as barriers by researchers, as the interchange of 
data between different programs usually requires some programming experience. The 
advent of visual workflow/ data pipelining environments diminished the problem at 
some extent. These computational environments provide the ability to graphically 
layout or build protocols and workflows, which can be reused, extended or rerun later 
also by other users [51].  
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[4–7], not alphabetical. If tables and figure legends contain any refs in addition to those 
cited in the main text, main text refs must be numbered first, followed by additional refs in 
the tables, followed by additional refs in the figure legends. 
 
 Acknowledgements: placed before reference list, should not acknowledge grants or original 
research contributors. 
 
 Algebra: numerical variables in italic; categories and groups in roman; vectors in bold 
 
 Define all abbreviations on first mention 
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•  Reference lists 
How many references? Please see  Article type table for number of references 
allowed. 
 
  Unpublished work, PhD theses and URLs/website addresses must be cited in main text, 
        not in reference lists. 
 
 Unpublished work:  cited in main text in parentheses as: (Q. Cumber-Patch et al., 
unpublished). 
 
 PhD  theses: cited in main text in parentheses: (R. Arthur Goode, PhD thesis, University 
of Hawaii,  1988). 
 
 URLs/website addresses: cited in main text in parentheses: (see: http://www.xxx.yyy.zzz). 
 
 References in main text, boxes and figures are numbered, and listed at the end of the 
main text. 
 
 In tables, references should be cited in numbers, in a separate column, and listed at 
the end of the main text. 
 
 References listed in order of citation, not alphabetically, with one reference per number. 
 
 For journal references: please give authors’ names (if two authors, print both names separated by ‘and’; 
if three or more authors, use et al. after first author); date (in parentheses); title (in roman text); 
abbreviate journal name using Biological Abstracts; volume; and complete page range. For example: 
1 Gold, B. (2002) Effect of cationic charge localization on DNA structure. Biopolymers 65, 173–179 
2 Han, Y. and Barillas-Mury, C. (2002) Implications of Time Bomb model of ookinete invasion of midgut cells. Insect 
Biochem. Mol. Biol. 32, 1311 
3 Gruber, D.M. et al. (1999) Progesterone and neurology. Gynecol. Endocrinol. 4, 41–45 
4 Jovani, R. Malaria transmission, sex ratio, and erythrocytes with two gametocytes. Trends Parasitol. (in press) 
 
 For online journal references: please give authors’ names (as above); date (in parentheses); title (in 
roman text); abbreviate journal name using Biological Abstracts; the digital object identifier (DOI) number; 
and the website of the journal. For example: 
5 Jiang, J.C. et al. (2000) An intervention resembling caloric restriction prolongs life span and retards aging in yeast. 
FASEB J. DOI: 10.1096/fj.00-242fje (http://www.fasebj.org) 
 
 For book references: 
For whole books: please give editors’ names; date (in parentheses); title (in italics); and publisher. For 
example: 
1 Chowdhury, N. and Alonso Aguirre, A., eds (2001) Helminths of Wildlife, Science Publishers Inc. 
For book chapters: please give chapter authors; date (in parentheses); chapter title; book title (in italics); 
editors’ names; page numbers and publisher. For example: 
35 Clutton-Brock, T. and Godfray, H.C.J. (1991) Parental investment. In Behavioural Ecology (3rd edn) (Krebs, J.R. and 
Davies, N.B., eds), pp. 234–262, Blackwell 
 
 For patent references: 
23 Bloggs, J. et al. Company name that actually owns the patent. Title of patent, Code 
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•  Accession numbers 
 
Accession numbers are unique  identifiers in bioinformatics allocated to nucleotide and protein sequences to 
allow tracking of different versions of that sequence record and the associated sequence in a data repository 
[e.g., databases at the National Center for Biotechnical Information (NCBI) at the National Library of 
Medicine ('GenBank') and the Worldwide Protein Data Bank]. There are different types of accession numbers 
in use based on the type of sequence cited, each of which uses a different coding. Authors should explicitly 
mention the type of accession number together with the actual number, bearing in mind that an error in a 
letter or number can result in a dead link in the online version of the article. Please use the following format: 
accession number type ID: xxxx (e.g., MMDB ID: 12345; PDB ID: 1TUP). Note that in the final version of 
the electronic copy, accession numbers will be linked to the appropriate database, enabling readers to go 
directly to that source from the article 
 
Possible ways of citing accession numbers  in the text: 
1 Sequences for introns 1 and 21 (NH0349G04: accession number  AC008172.1) sequenced in 
GenBank. 
 
  2 The accession numbers for each sequence are as follows:  BAA78620 (Amphihox1),  P09022    
  (mouse Hox-A1)  and CAB57787 (Drosophila Lab). 
 
 
• Additional material (Boxes, Tables and Figures) 
Please see Article Type Table for the number of separate pieces of additional material 
allowed. 
Boxes 
Boxes can be used for additional explanatory material, which, although essential, interrupts the flow of the text 
(e.g. mathematical models, glossaries, methodologies and historical notes). Can contain figures and tables. 
Should be <500 words long. 
 
 Have you cited all boxes in the main text? 
 
 Please provide a single-sentence title for the box (<8 words), double-space box text (500 words max.). 
 
 Explain all abbreviations at first mention unless already defined in main text. 
 
  
Tables 
 Have you cited all tables in the text? 
 Please provide single-sentence title for the table, double-space and run-on all text. 
 Footnotes: help the reader to understand the table without referring to the main text. Use superscript 
lettersa,b  to refer to footnotes in alphabetical order. All abbreviations, symbols etc. must be explained in a 
footnote unless abbreviations have been previously defined in the main text. 
 References cited in tables should be in a separate column and listed in the main reference list (in sequence 
from end of main reference list). 
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 Figures 
 Have you cited all figures in the main text and/or box text? 
 Have you obtained permission to reproduce copyrighted material (i.e. material, such as figures, tables or 
excerpts, that has already been published elsewhere) from the copyright owners of that material 
 Have you acknowledged, in the figure legend, the original source of previously published material? 
 Please supply individual, editable files of each of your figures. These files should be in the format in which 
they were originally created, rather than imported into other programs. 
 Figure labels: always first letter capital, then remainder lower-case (not bold or italic, except for species). 
 Please provide a figure legend to help the reader to understand the figure without referring to the main 
text, including: a short title; scale bar (if appropriate); references (should be listed in the main reference 
list, in sequence from end of list); and explain all abbreviations, symbols and colour codes etc. Please place 
figure legends at the end of main text (after reference list) and not next to the figure. Figure legends should 
concisely describe what is shown in the figure, and should allow the figure to stand alone without reference 
to the text. 
 All abbreviations used in figure are explained in legend. 
For figure submission guidelines please see: 
http://www.elsevier.com/artworkinstructions 
 
